VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine
The Lancet on Twitter: "NEW—Tetravalent dengue vaccine (TAK-003) was well tolerated and efficacious against symptomatic #dengue in children aged 4-16 years regardless of serostatus before immunisation: a randomised, placebo-controlled, phase 3 trial
wave1presentation Foreign Issuer Report 6-K
TAK-003 vaccine: Trial shows Continued Protection against Dengue Fever - YouTube
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | NEJM
TAK-003 - News, Articles etc. - European Pharmaceutical Review
Takeda: Dengue Vaccine Candidate Works Without Big Safety Risks
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Cross-reactivity of T cell responses following TAK-003... | Download Scientific Diagram
Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration - Headlines of Today